- Nguyen Huu N, Ryder W, Zeps N, Flasza M, Chiu M, Hanby A, Poulsom R, Clarke R, Baron M. Tumour-promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicator J Pathol 2008; 216: 93–102
- Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer 98: 1562-1569
- Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW. Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma. Journal of Thoracic Oncology. 3(8):858-864
- Catchpoole D.R., Guo D., Jiang H., Biesheuvel C. Predicting outcome in childhood acute lymphoblastic leukaemia using gene expression profiling: Prognostication or protocol selection? Blood 2008; 111(4): 2486-2487
- Margetts C.D.E., Morris M., Astuti D., Gentle D.C., Cascon A., McRonald F.E., Catchpoole D.R., Robledo M., Neumann H.P.H., Latif F. and Maher E.R. Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma Endocrine-Related Cancer (2008) 15 777–786
- Natrajan R, Warren W, Messahel B, Reis-Filho JS, Brundler MA, Dome JS, Grundy PE, Vujanic G, Pritchard Jones K, Jones C. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours J Clin Pathol 2008;61:95-102
- Shehata M, Bièche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, Byrne JA. Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52 Clin Cancer Res 2008;14:5050-5060
- Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, Diasio RB, Iacopetta B. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy Annals of Oncology 19: 915–919, 2008
- Tothill RW, Tinker AV, George J, Brown R, Fox SB, Johnson DS, Trivett, MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung J, Chiew, Y-E, Haviv I, AOCS Study Group, Gertig, D, deFazio A and Bowtell DDL. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clin Cancer Res 2008;14:5198-5208
- Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, Pryor K, Wain GV, Brand A, Byth K, Kennedy C, Rizos H, Harnett PR, and deFazio, A. Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer Clin Cancer Res 2008;14:6924-6932
- Anglesio, M., Arnold, J., George, J., Tinker, A., Tothill, R., Waddell, N., Simms, L., Locandro, B., Fereday, S., Traficante, N., Russell, P., Sharma, R., Birrer, M., Australian Ovarian Cancer Study Group, deFazio, A., Chenevix-Trench, G., and Bowtell, D. Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors Mol Cancer Res 2008;6:1678-1690
- Gomes, L., Mackie, N., Catchpoole, D., Henwood, T. Test and Teach - In a fix about immunohistochemistry on 60 year old tissue blocks?. Journal of Histotechnology. 2008; 8:125.
Categories: